In summary, JAK mutations, including JAK2 fusion genes brought about by cytogenetically visible translocations, may be pathogenetically significant in CTCL, although it is not yet known how widespread their involvement is. The gene discussed is JAK2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.